PT3004155T - Composto peptídico - Google Patents

Composto peptídico

Info

Publication number
PT3004155T
PT3004155T PT147299762T PT14729976T PT3004155T PT 3004155 T PT3004155 T PT 3004155T PT 147299762 T PT147299762 T PT 147299762T PT 14729976 T PT14729976 T PT 14729976T PT 3004155 T PT3004155 T PT 3004155T
Authority
PT
Portugal
Prior art keywords
peptide compound
peptide
compound
Prior art date
Application number
PT147299762T
Other languages
English (en)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PT3004155T publication Critical patent/PT3004155T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT147299762T 2013-05-28 2014-05-27 Composto peptídico PT3004155T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013111893 2013-05-28

Publications (1)

Publication Number Publication Date
PT3004155T true PT3004155T (pt) 2021-12-22

Family

ID=50942304

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147299762T PT3004155T (pt) 2013-05-28 2014-05-27 Composto peptídico

Country Status (35)

Country Link
US (2) US10087229B2 (pt)
EP (1) EP3004155B1 (pt)
JP (2) JP6429799B2 (pt)
KR (1) KR102229051B1 (pt)
CN (1) CN105209485B (pt)
AP (1) AP2015008781A0 (pt)
AR (1) AR096440A1 (pt)
AU (1) AU2014272500B2 (pt)
CA (1) CA2908581C (pt)
CL (1) CL2015003031A1 (pt)
CY (1) CY1124790T1 (pt)
DK (1) DK3004155T3 (pt)
DO (1) DOP2015000261A (pt)
EA (2) EA035813B1 (pt)
EC (1) ECSP15044389A (pt)
ES (1) ES2900744T3 (pt)
GE (1) GEP201706762B (pt)
HR (1) HRP20212014T1 (pt)
HU (1) HUE057361T2 (pt)
IL (1) IL242005B (pt)
LT (1) LT3004155T (pt)
MA (1) MA38472B1 (pt)
MX (2) MX373436B (pt)
MY (1) MY172744A (pt)
PE (1) PE20151770A1 (pt)
PH (1) PH12015502391B1 (pt)
PL (1) PL3004155T3 (pt)
PT (1) PT3004155T (pt)
SG (1) SG11201507934PA (pt)
SI (1) SI3004155T1 (pt)
TN (1) TN2015000451A1 (pt)
TW (1) TWI638831B (pt)
UA (1) UA118558C2 (pt)
UY (1) UY35589A (pt)
WO (1) WO2014192284A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096440A1 (es) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
JO3575B1 (ar) * 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
CN104846061A (zh) * 2015-05-07 2015-08-19 中国药科大学 一种glp-1受体激动剂的受体亲和力测定方法
CN105388239B (zh) * 2015-12-18 2018-01-05 兆科药业（合肥）有限公司 一种多肽固相合成的监测方法
EP3467106B1 (en) * 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Peptide compound
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20190211A1 (ar) * 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
MX2020007410A (es) * 2018-01-23 2020-11-09 Gila Therapeutics Inc Formulaciones, composiciones y métodos farmacéuticos de péptido yy.
RU2020136305A (ru) 2018-05-04 2022-05-05 Ново Нордиск А/С Производные gip и пути их применения
CN110818771B (zh) * 2018-08-14 2023-01-17 陈铭 使用氨基酸离子液体的羰基硫介导多肽合成
JP2022503793A (ja) * 2018-09-24 2022-01-12 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
WO2020067575A1 (en) * 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
EP4017866A1 (en) * 2019-08-19 2022-06-29 Eli Lilly and Company Methods of making incretin analogs
WO2021066600A1 (ko) 2019-10-04 2021-04-08 한미약품 주식회사 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
JP2023519446A (ja) * 2020-03-25 2023-05-10 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物のｑｄ投薬及びその使用
JP7736315B2 (ja) * 2020-03-31 2025-09-09 アンタロス メディカル アクティエボラーグ イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト
CA3184723A1 (en) 2020-07-22 2022-01-27 Patrick J. KNERR Glp-1 and gip receptor co-agonists
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
EP4345105A4 (en) 2021-06-01 2025-04-23 Nanjing Zhihe Medicine Technology Co., Ltd Polypeptide derivative with dual targeted activation of GLP-1R and GIPR, manufacturing process therefor and use thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
IL318349A (en) * 2022-07-13 2025-03-01 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Glp-1/gip dual agonist, preparation method and use thereof
CA3262093A1 (en) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Pharmaceutical Formulations and Methods for the Treatment of Metabolic and Liver Disorders
WO2024059674A1 (en) 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds
JP2026502943A (ja) 2022-12-30 2026-01-27 アルギファルマ エーエス 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
KR20240167410A (ko) 2023-05-19 2024-11-26 주식회사 아울바이오 티르제파타이드를 포함하는 미립구, 이의 제조방법, 및 이를 포함하는 약학적 조성물
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
KR20260032481A (ko) 2023-06-30 2026-03-09 질랜드 파마 에이/에스 병용 요법
WO2025108381A1 (zh) * 2023-11-22 2025-05-30 杭州中美华东制药有限公司 Glp-1r/gipr双靶点激动剂在制备动物药中的用途
WO2025114501A1 (en) 2023-11-30 2025-06-05 Novo Nordisk A/S Tri-agonists of the glp-1, gip, and amylin receptors
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
TW202542174A (zh) * 2023-12-29 2025-11-01 大陸商杭州中美華東製藥有限公司 Glp-1/gip雙激動劑的固相合成方法
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025149041A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的鼻腔递送药物组合物
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ES2237790T3 (es) 1996-11-12 2005-08-01 Novo Nordisk A/S Uso de peptidos glp-1.
WO1999047161A1 (en) 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
PL205713B1 (pl) * 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
AU5675701A (en) 2000-05-16 2001-11-26 Sanwa Kagaku Kenkyusho Co Agents for preventing or ameliorating insulin resistance and/or obesity
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
WO2006136374A2 (en) 2005-06-20 2006-12-28 Develogen Aktiengesellschaft Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells
AU2007272954A1 (en) 2006-07-11 2008-01-17 Harkness Pharmaceuticals, Inc. Methods of treating obesity using satiety factors
WO2008021560A2 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
PE20080840A1 (es) 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP2224945B1 (en) 2007-11-23 2012-05-16 Michael Rothkopf Methods of enhancing diabetes resolution
TWI474835B (zh) * 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
CA2733006A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
DK2373681T3 (en) 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2528618A4 (en) * 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
CA2822617A1 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
KR102066987B1 (ko) 2011-06-10 2020-01-16 노보 노르디스크 에이/에스 폴리펩티드
US9453062B2 (en) * 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
WO2013003449A2 (en) 2011-06-27 2013-01-03 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
CN107266558A (zh) 2011-09-06 2017-10-20 诺沃—诺迪斯克有限公司 Glp‑1衍生物
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
US20150182461A1 (en) 2012-06-19 2015-07-02 Massachussets Institute Of Technology Mass Production and Size Control of Nanoparticles Through Controlled Microvortices
CN104583233B (zh) 2012-06-21 2018-10-23 印第安纳大学研究及科技有限公司 表现出gip受体活性的胰高血糖素的类似物
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
WO2014096179A1 (en) 2012-12-19 2014-06-26 Novo Nordisk A/S Novel glp-1 receptor agonists with cholesterol efflux activity
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
AU2014230472A1 (en) 2013-03-14 2015-10-01 Medimmune Limited Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
AR096440A1 (es) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
JP2018012644A (ja) 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物

Also Published As

Publication number Publication date
MX2015015464A (es) 2016-03-21
MX373436B (es) 2020-04-30
TW201514203A (zh) 2015-04-16
EA202090593A3 (ru) 2020-08-31
KR102229051B1 (ko) 2021-03-16
MX2019010531A (es) 2019-10-15
EP3004155A1 (en) 2016-04-13
GEP201706762B (en) 2017-10-25
ES2900744T3 (es) 2022-03-18
NZ712421A (en) 2021-04-30
US10087229B2 (en) 2018-10-02
MX388826B (es) 2025-03-20
EA035813B1 (ru) 2020-08-14
US9200051B2 (en) 2015-12-01
MY172744A (en) 2019-12-11
LT3004155T (lt) 2021-12-27
KR20160010446A (ko) 2016-01-27
CA2908581A1 (en) 2014-12-04
PL3004155T3 (pl) 2022-02-07
PH12015502391A1 (en) 2016-02-22
PE20151770A1 (es) 2015-12-11
IL242005B (en) 2019-05-30
HUE057361T2 (hu) 2022-05-28
AP2015008781A0 (en) 2015-10-31
JP6429799B2 (ja) 2018-11-28
JP6570705B2 (ja) 2019-09-04
SI3004155T1 (sl) 2022-02-28
BR112015027596A2 (pt) 2017-12-05
TWI638831B (zh) 2018-10-21
PH12015502391B1 (en) 2019-05-31
UY35589A (es) 2014-12-31
UA118558C2 (uk) 2019-02-11
SG11201507934PA (en) 2015-10-29
MA38472B1 (fr) 2018-09-28
AU2014272500B2 (en) 2018-03-08
DOP2015000261A (es) 2015-12-31
AU2014272500A1 (en) 2015-11-05
JP2018168167A (ja) 2018-11-01
CY1124790T1 (el) 2022-11-25
HRP20212014T1 (hr) 2022-04-01
HK1216757A1 (en) 2016-12-02
WO2014192284A1 (en) 2014-12-04
JP2016520511A (ja) 2016-07-14
EA201591891A1 (ru) 2016-01-29
MA38472A1 (fr) 2018-01-31
ECSP15044389A (es) 2017-08-31
US20140357552A1 (en) 2014-12-04
CN105209485B (zh) 2019-12-10
DK3004155T3 (da) 2022-01-03
CA2908581C (en) 2021-07-13
EA202090593A2 (ru) 2020-06-30
CN105209485A (zh) 2015-12-30
US20160052988A1 (en) 2016-02-25
EP3004155B1 (en) 2021-11-24
CL2015003031A1 (es) 2016-06-24
AR096440A1 (es) 2015-12-30
TN2015000451A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
IL242005B (en) A peptide compound
IL249518B (en) A compound that inhibits trk
GB201302368D0 (en) Compound
IL241695B (en) Pyridinylpyrazoloquinoline compounds
ZA201600729B (en) Peptides
ZA201504986B (en) Peptide
HUE050164T2 (hu) Új négy-CTL epitóp-kapcsolt peptid
ZA201504987B (en) Peptide
GB201315130D0 (en) Peptides
GB201408643D0 (en) Compound
GB201307331D0 (en) Compound
GB201316660D0 (en) Peptides
GB201322438D0 (en) Compound
GB201300381D0 (en) Peptides
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound